Moreover, it could be considered the preferred alternative to [18F]FDG in cancers with low to moderate uptake.99 Recently, Liu et al. compared the performance of [18F]AlF-FAP-2286 with that of established radiopharmaceuticals in a preclinical study. This evidence concerns the gene FAP and cancer.